Loading stock data…
CRNX
$37.72+0.24 (+0.63%)
Market OpenUpdated 11:49 AM EDT
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Crinetics Pharmaceuticals, Inc. in the Healthcare sector is trading at $37.78. Wall Street consensus targets $83.21 (14 analysts), implying a +120.3% move over the next 12 months. The stock is currently 35% below its 52-week high of $57.99, remaining 8.0% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +120.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$37.72
Potential Downside
0%
Whystock Fair Value$37.72
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Mean target$83.21+120.6%
Range$55.00 – $97.00
Fundamentals
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.09B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.31
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-37.28%
Volume
Today's trading volume
259,177
Recent News
Industry Analysts Just Upgraded Their Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Revenue Forecasts By 11%
Shareholders in Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX ) may be thrilled to learn that the analysts have just...
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX ) shareholders are probably feeling a little disappointed, since its...
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Momentum
Recent share performance and what it might signal Crinetics Pharmaceuticals (CRNX) has caught investor attention after a 4.2% move in the latest session, following gains of 12.1% over the past week and 13.2% over the past month. See our latest analysis for Crinetics Pharmaceuticals. While the latest 1 day share price return of 4.23% highlights fresh interest around $43.48, the 90 day share price return of a 3.99% decline and year to date share price return of a 6.97% decline contrast with...
Crinetics (CRNX) Q1 2026 Earnings Transcript
As a reminder, we'll be making forward-looking statements, and I invite you to learn more about the risks and uncertainties associated with these statements as disclosed in our SEC filings. Such forward-looking statements are not a guarantee of performance, and the company's actual results could differ materially from those stated or implied in such statements due to risks and uncertainties associated with the company's business. In particular, today, we will be reviewing launch progress to date, our commercialization plans, future performance and other data about the acromegaly market, which are all necessarily subject to a high degree of uncertainty and risk.
Crinetics Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Moby summary of Crinetics Pharmaceuticals, Inc.'s Q1 2026 earnings call